Hermetica Superfood Encyclopedia
The Short Answer
Yohimbe bark contains the indole alkaloid yohimbine, which functions as a selective α2-adrenergic receptor antagonist, blocking presynaptic receptors to enhance norepinephrine release and modulate sympathetic nervous system tone. Clinical pharmacokinetic data show oral yohimbine bioavailability of 22–33% (range 4–87%), with therapeutic plasma concentrations of 50–300 ng/mL achieved at doses of 5–10 mg administered two to three times daily, supporting its use in erectile dysfunction and as an adrenergic stimulant.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary Keywordyohimbe benefits
Yohimbe — botanical close-up
Health Benefits
**Erectile Dysfunction Support**
Yohimbine's blockade of α2-adrenoceptors on penile vasculature increases local norepinephrine availability and facilitates nitric oxide-mediated vasodilation, promoting engorgement; historical and small clinical studies have supported its use as an aphrodisiac and mild pro-erectile agent.
**Sympathomimetic and Adrenergic Stimulation**
By inhibiting presynaptic α2-autoreceptors, yohimbine disinhibits norepinephrine release from sympathetic nerve terminals, raising circulating catecholamines and increasing heart rate and blood pressure transiently.
**Fat Mobilization and Weight Management**
Elevated norepinephrine resulting from α2-receptor blockade activates β-adrenergic receptors on adipocytes, stimulating lipolysis; this mechanism has prompted investigation of yohimbine as a fat-loss adjunct, particularly for stubborn, α2-receptor-dense adipose depots.
**Autonomic Nervous System Research Tool**
Yohimbine is used experimentally to probe noradrenergic function, induce controlled anxiogenic states, and assess sympathetic reserve in clinical and neuroscience research contexts, given its reproducible adrenergic activation profile.
**Psychoactive and Mood-Alerting Effects**
Noradrenergic activation of the locus coeruleus and HPA axis by yohimbine produces arousal, heightened alertness, and anxiogenic responses; at sub-threshold doses, these effects may translate to perceived energy enhancement.
**Traditional Aphrodisiac and Sexual Function**
Indigenous West African preparations of yohimbe bark decoctions have long been used to enhance libido and sexual performance, a use that informed 20th-century pharmacological isolation of yohimbine and its eventual approval in some countries as a prescription agent for psychogenic erectile dysfunction.
Origin & History
Natural habitat
Pausinystalia johimbe is an evergreen tree native to the rainforests of West and Central Africa, particularly Cameroon, Nigeria, Gabon, and the Democratic Republic of Congo, where it thrives in humid, tropical lowland forest conditions. The bark of mature trees, especially from older branches, contains the highest concentrations of bioactive alkaloids and has been harvested for centuries by indigenous peoples. Wild-harvested bark remains the primary commercial source, with no significant cultivated supply, raising sustainability concerns given increased global demand for standardized extracts.
“Yohimbe bark has been used for centuries by indigenous peoples of West and Central Africa, particularly in Cameroon and Nigeria, as a traditional aphrodisiac and sexual performance enhancer, with bark decoctions consumed before sexual activity or ceremonial rituals. The tree's medicinal reputation was documented by European botanists and physicians during the colonial era, with the German pharmacologist Madaus recording its uses in his 1938 compendium Lehrbuch der Biologischen Heilmittel, which helped catalyze western pharmacological interest. Yohimbine was first isolated from the bark in the late 19th century, and by the mid-20th century it had been investigated as a pharmaceutical agent for erectile dysfunction, achieving prescription status in some countries before the advent of PDE5 inhibitors. Traditional preparation involved harvesting bark strips from older, mature branches — recognized empirically as having greater potency — and preparing aqueous decoctions or mixing powdered bark into food or beverage preparations for communal or individual use.”Traditional Medicine
Scientific Research
The clinical evidence base for yohimbe bark and isolated yohimbine is limited in scale and methodological quality; no large, multicenter randomized controlled trials with robust sample sizes have been published specifically for the whole bark preparation, and most human data derive from small pharmacokinetic studies and open-label or poorly controlled trials. A key pharmacokinetic study established oral bioavailability of 22–33% (with extreme inter-individual variability of 4–87%) following doses of 5.4–21.6 mg administered three times daily for six days, demonstrating no significant drug accumulation, a rapid absorption half-life of approximately 10 minutes, and an elimination half-life of approximately 30 minutes. A 2015 analysis of 49 commercial yohimbe supplements revealed highly inconsistent yohimbine content ranging from 0 to over 12 mg per dose, raising serious questions about the translational relevance of any efficacy or safety data derived from uncharacterized bark preparations. The overall evidence tier for yohimbe as a whole botanical is preliminary, though isolated pharmaceutical-grade yohimbine HCl has modestly stronger pharmacological characterization; honest appraisal places the botanical evidence at the level of preclinical and early-phase human pharmacokinetics rather than confirmed therapeutic efficacy.
Preparation & Dosage
Traditional preparation
**Standardized Bark Extract (capsule/tablet)**
95–105 mg/g total alkaloids calculated as yohimbine; typical dose providing 5–10 mg yohimbine per serving, taken 2–3 times daily with meals to reduce gastrointestinal irritation
Target .
**Crude Bark Powder**
7–115 mg/g yohimbine depending on bark age and analytical method), making dose titration unreliable
Historically prepared as a decoction by simmering dried bark in water; potency is highly variable (.
**Liquid Extract**
Alcoholic or aqueous tinctures of bark; standardization is inconsistent across commercial products, with some retaining as little as ≤7% of original bark yohimbine content.
**Yohimbine Hydrochloride (pharmaceutical grade)**
5–10 mg two to three times daily are pharmacologically characterized; preferred for research and precise therapeutic use over whole bark
Synthetic isolated alkaloid salt; doses of .
**Timing**
Best absorbed on an empty stomach for maximum peak plasma concentration (reached in under 1 hour); however, cardiovascular and anxiogenic side effects are more pronounced in fasted state.
**Dose Titration**
5–5 mg per dose to assess individual tolerance before escalating to therapeutic range, given the extreme inter-individual variability in bioavailability (4–87%)
Begin at 2..
Nutritional Profile
Yohimbe bark is not consumed as a food source and contributes negligible macronutrient value to diet; proximate analysis of bark powder indicates approximately 62.27% carbohydrates and 2.67% ash, with minimal protein and lipid fractions. The dominant pharmacologically active constituents are alkaloids, with yohimbine comprising the largest fraction (7–115 mg/g depending on analytical method and bark maturity), followed by α-yohimbine (rauwolscine) and raubasine, with a total of 55 alkaloids identified in the bark. Secondary phytochemicals include phenolics (present at the highest concentration among non-alkaloid constituents), flavonoids, tannins, saponins, oxalate, and phytate, which may modulate absorption and contribute to gastrointestinal effects. The lipophilicity of yohimbine facilitates passive intestinal absorption, but extensive first-pass hepatic metabolism and high plasma protein binding (82%) limit systemic exposure and contribute to its characteristically variable bioavailability.
How It Works
Mechanism of Action
Yohimbine (C21H26N2O3, MW 354.44 g/mol) acts primarily as a competitive antagonist at presynaptic and postsynaptic α2-adrenergic receptors, removing tonic inhibitory control over norepinephrine release from sympathetic neurons and thereby elevating synaptic norepinephrine concentrations. This increased adrenergic tone activates downstream β-adrenergic and postsynaptic α1-adrenergic signaling, accounting for cardiovascular stimulation, lipolysis in adipose tissue, and vasodilatory effects in certain vascular beds via nitric oxide modulation in renal and penile circulation. Yohimbine undergoes primary hepatic metabolism via CYP3A4 to the active metabolites 11-hydroxy-yohimbine (major) and 10-hydroxy-yohimbine, with plasma protein binding of 82% for parent compound, 43% for the 11-hydroxy metabolite, and 32% for the 10-hydroxy metabolite, contributing to a highly variable pharmacokinetic profile. Additionally, yohimbine activates the HPA stress axis through noradrenergic stimulation, producing anxiogenic effects, and its co-alkaloid rauwolscine (α-yohimbine) contributes parallel adrenergic stimulation with a similar receptor antagonism profile.
Clinical Evidence
Human clinical investigation of yohimbe and yohimbine has focused primarily on pharmacokinetics, erectile dysfunction, and adrenergic stimulation rather than definitive efficacy endpoints in large trials. Pharmacokinetic characterization shows therapeutic plasma concentrations of 50–300 ng/mL are achievable at 5–10 mg doses two to three times daily, but the high inter-individual variability in AUC (0.5–106 μg·min/mL for yohimbine vs. the more consistent 39–152 μg·min/mL for 11-hydroxy-yohimbine) complicates dose prediction. Small historical trials using pharmaceutical yohimbine HCl for psychogenic erectile dysfunction suggested modest benefit over placebo, contributing to its prior prescription status in some jurisdictions, but these studies lacked the rigor of modern RCT standards. Confidence in the clinical evidence remains low for whole yohimbe bark preparations, and the absence of large randomized trials with pre-registered protocols, standardized bark extracts, and validated outcome measures means that efficacy claims for the commercial supplement form are not well-substantiated.
Safety & Interactions
Yohimbe and yohimbine carry a meaningful adverse effect profile driven by their adrenergic mechanism: common side effects at therapeutic doses (5–10 mg yohimbine) include anxiety, agitation, tachycardia, hypertension, headache, dizziness, and gastrointestinal upset, with severity amplified by the high inter-individual variability in absorption and the stimulation of the HPA stress axis. Critical drug interactions arise through CYP3A4-mediated metabolism — inhibitors of CYP3A4 (such as certain azole antifungals, macrolide antibiotics, and grapefruit juice) can substantially increase yohimbine plasma levels, while inducers may reduce efficacy; concurrent use with antidepressants (particularly MAOIs and tricyclics) or other adrenergic agents poses serious risk of hypertensive crisis or serotonin syndrome. Contraindications include cardiovascular disease, hypertension, anxiety disorders, renal impairment (given nitric oxide effects on renal circulation), hepatic disease, peptic ulcer disease, and any condition exacerbated by sympathetic activation; the European Union's food safety assessment has deemed yohimbe bark unsafe for food use due to unacceptable toxicity risk at doses required for pharmacological effect. Yohimbe is contraindicated in pregnancy and lactation due to its adrenergic and uterotonic potential; no established safe maximum dose for the whole bark preparation exists, and commercial supplement variability (0–12+ mg yohimbine per dose) makes safe self-administration particularly challenging.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Pausinystalia johimbeCorynanthe johimbeYohimbeheJohimbeYohimbine bark
Frequently Asked Questions
What is the recommended dose of yohimbe or yohimbine?
For isolated yohimbine hydrochloride, the pharmacologically characterized therapeutic dose is 5–10 mg taken two to three times daily, targeting plasma concentrations of 50–300 ng/mL. For whole yohimbe bark extracts, standardized preparations delivering 95–105 mg/g total alkaloids are preferred, but significant variability across commercial supplements (ranging from 0 to over 12 mg yohimbine per dose) makes precise dosing challenging. New users should begin at 2.5–5 mg per dose to assess individual tolerance before escalating, given the extreme inter-individual variability in bioavailability (4–87%).
Does yohimbe actually work for erectile dysfunction?
Yohimbine, the primary alkaloid in yohimbe bark, has a pharmacologically plausible mechanism for supporting erectile function: it blocks α2-adrenergic receptors in penile vasculature, enhancing norepinephrine availability and complementing nitric oxide-mediated vasodilation. Small historical clinical trials using pharmaceutical-grade yohimbine HCl for psychogenic erectile dysfunction showed modest benefit over placebo, sufficient for prescription status in some countries before PDE5 inhibitors became available. However, no large, rigorous randomized controlled trials with standardized whole yohimbe bark extracts have confirmed efficacy, so evidence remains limited and the commercial supplement form cannot be assumed equivalent to studied pharmaceutical preparations.
What are the side effects of taking yohimbe?
The most commonly reported side effects of yohimbe and yohimbine at therapeutic doses (5–10 mg) include anxiety, agitation, rapid heart rate (tachycardia), elevated blood pressure, headache, dizziness, and gastrointestinal upset such as nausea. These effects arise directly from yohimbine's mechanism — blocking α2-adrenergic receptors causes a surge in norepinephrine and activation of the HPA stress axis, producing pronounced sympathomimetic responses. Inter-individual variability in bioavailability (4–87%) means some people experience intense side effects at doses that others tolerate without issue, making careful dose titration essential.
Can yohimbe help with weight loss or fat burning?
Yohimbine's α2-adrenergic receptor antagonism disinhibits norepinephrine release, which activates β-adrenergic receptors on adipocytes to stimulate lipolysis — the biochemical basis for its inclusion in thermogenic and fat-loss supplements. This mechanism is particularly relevant for α2-receptor-dense adipose depots (such as abdominal and gluteal fat) that are resistant to catecholamine-stimulated lipolysis. While the pharmacological rationale is sound, large-scale clinical trials specifically demonstrating meaningful fat loss from yohimbe bark supplements in humans are lacking; the evidence for isolated yohimbine combined with caloric restriction or exercise is limited to small studies.
Is yohimbe safe to take with other supplements or medications?
Yohimbine is metabolized primarily by CYP3A4, meaning drugs that inhibit this enzyme — including certain antifungals (ketoconazole), macrolide antibiotics (erythromycin), and grapefruit juice — can significantly elevate yohimbine plasma levels and increase adverse effects. Concurrent use with MAO inhibitors, tricyclic antidepressants, or other adrenergic agents poses serious risk of hypertensive crisis or excessive sympathomimetic effects, and combining yohimbe with caffeine or other stimulants additively increases cardiovascular strain. Yohimbe is contraindicated in individuals with cardiovascular disease, uncontrolled hypertension, anxiety disorders, or renal impairment, and should not be used during pregnancy or lactation.
Is yohimbe safe during pregnancy or while breastfeeding?
Yohimbe is not recommended during pregnancy or breastfeeding due to insufficient safety data and its sympathomimetic effects, which could potentially affect blood pressure and fetal development. Women who are pregnant or nursing should avoid yohimbe and consult their healthcare provider before use.
How does yohimbine from yohimbe bark compare to synthetic yohimbine supplements?
Yohimbe bark extract contains yohimbine along with other alkaloids, while pharmaceutical-grade yohimbine is an isolated, standardized compound with more predictable dosing and potency. Synthetic yohimbine allows for precise dosing and clinical consistency, whereas whole yohimbe extracts may have variable alkaloid content depending on the source and processing method.
Who should avoid taking yohimbe supplements?
Individuals with hypertension, heart disease, anxiety disorders, or kidney/liver impairment should avoid yohimbe due to its stimulant effects and potential to elevate blood pressure and heart rate. Additionally, those taking stimulants, certain psychiatric medications, or blood pressure medications should not use yohimbe without explicit medical clearance.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w yohimbe-pausinystalia-johimbe curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
